Glentek/Riluzol (riluzole) vs Lunasin (lunasin)

Riluzole, marketed as Rilutek and sometimes referred to as Glentek, is an FDA-approved medication primarily used to slow the progression of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. It works by reducing the release of glutamate, which is thought to be involved in the damage of motor neurons. In contrast, Lunasin is a naturally occurring peptide that is being studied for its potential health benefits, including anti-inflammatory and anticancer properties, but it is not a medication and does not have FDA approval for the treatment of specific diseases. When deciding between these two, it is important to consider that Riluzole is a drug with a specific indication for ALS, while Lunasin is a dietary supplement with a different range of potential benefits that are not yet fully validated by clinical trials for any particular condition.

Difference between Glentek/Riluzol and Lunasin

Metric	Glentek/Riluzol (riluzole)	Lunasin (lunasin)
Generic name	Riluzole	Lunasin
Indications	Amyotrophic lateral sclerosis (ALS)	Not established for specific medical conditions; researched for potential anti-inflammatory, antioxidant, and anticancer properties
Mechanism of action	Reduces glutamate release, thus potentially slowing down neuronal damage	Believed to influence epigenetic regulation and may have a role in modulating inflammation and oxidative stress
Brand names	Glentek, Rilutek, Teglutik	Lunasin is not sold under a brand name for medical use
Administrative route	Oral	Oral (as a dietary supplement)
Side effects	Dizziness, gastrointestinal disturbances, liver function alterations, and others	Not well-documented; may vary depending on the source and form of lunasin consumed
Contraindications	Liver impairment, caution in patients with a history of neutropenia	Not well-established; caution advised for individuals with allergies to soy or related allergens
Drug class	Neuroprotective agent	Not classified as a drug; considered a bioactive peptide
Manufacturer	Sanofi-Aventis, Covis Pharma	Various dietary supplement manufacturers

Efficacy

Efficacy of Riluzole (Rilutek/Glentek) in ALS

Riluzole, marketed under the brand names Rilutek and Glentek, is the first medication approved by the FDA for the treatment of Amyotrophic Lateral Sclerosis (ALS). Clinical trials have demonstrated that riluzole can modestly prolong survival in individuals with ALS. The exact mechanism by which riluzole exerts its effects is not fully understood, but it is believed to reduce the release of glutamate, which is thought to be involved in the death of neurons in ALS. The efficacy of riluzole in ALS has been shown to extend survival by about two to three months on average, although individual responses can vary.

While riluzole does not reverse the damage already done by ALS, it can slow the progression of symptoms in some patients. The drug's impact on symptom progression is relatively modest, and it is more effective in the earlier stages of the disease. This has been evidenced by a slower decline in muscle strength and function in patients taking riluzole compared to those not receiving the drug. Due to its potential benefits, riluzole is often recommended for most patients diagnosed with ALS.

Efficacy of Lunasin in ALS

Lunasin is a peptide that has been explored for its potential therapeutic effects in ALS. However, it is important to note that as of the current knowledge cutoff date, lunasin is not approved by the FDA for the treatment of ALS. The interest in lunasin stems from its purported anti-inflammatory and neuroprotective properties, which could theoretically be beneficial in a disease like ALS that involves inflammation and neuronal degeneration. However, scientific evidence supporting the efficacy of lunasin in ALS is limited and more research is needed to establish its potential benefits.

Some preliminary studies and anecdotal reports have suggested that lunasin may have a positive impact on certain biomarkers or symptoms associated with ALS, but these findings are not conclusive. Large-scale, well-designed clinical trials are required to determine the true efficacy of lunasin in treating ALS. Until such data is available, the use of lunasin for ALS remains experimental and should be approached with caution. Patients interested in exploring treatments like lunasin should discuss the potential risks and benefits with their healthcare provider.

Regulatory Agency Approvals

Glentek/Riluzol

European Medical Agency (EMA), European Union
Therapeutic Goods Administration (TGA), Australia
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom
The Medicines Evaluation Board (MEB), The Netherlands

Lunasin

Food and Drug Administration (FDA), USA

Access Glentek/Riluzol or Lunasin today

If Glentek/Riluzol or Lunasin are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Glentek/Riluzol

Buy Lunasin

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: